Connect with us

Health

Statement from the Chief Public Health Officer of Canada on March 15, 2021 – Stockhouse

Published

 on


OTTAWA, ON , March 15, 2021 /CNW/ –

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks. Through the Wellness Together Canada online portal, people of all ages across the country can access immediate, free and confidential mental health and substance use supports, 24 hours a day, seven days a week.

As of March 15th , almost 3.0 million doses of COVID-19 vaccines have been administered across Canada . Federal, provincial and territorial authorities are working closely together to monitor vaccine safety following immunization with COVID-19 vaccines. To date, no unexpected vaccine safety issues have been identified . All adverse events are subject to review. All serious events undergo a detailed investigation to determine whether or not they are related to the vaccine. Information that indicates a potential link between a vaccine and a health event is considered a safety signal, which warrants appropriate action from the regulator.

Based on data up to March 5th , there have been 1,923 reports of adverse events following immunization (AEFI) with COVID-19 vaccines; these include any medical event that occurs following immunization, but is not necessarily related to the vaccine or the immunization process. A total of 214 AEFI reports to date – about 1 in 11,000 doses administered – were considered serious, such as a severe allergic reaction. Health Canada is aware of reports of adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine and would like to reassure Canadians that the benefits of the vaccine continue to outweigh its risks. At this time, there is no indication that the vaccine caused these events. None of the batches of the vaccine under investigation in Europe were shipped to Canada . The Government of Canada continues to work with international regulators, including the European Medicines Agency (EMA), to determine whether there is any need to take action in Canada .

As COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity. At the same time, the Public Health Agency of Canada is providing Canadians with regular updates on COVID-19 vaccines administered , vaccination coverage and ongoing monitoring of vaccine safety across the country. The following is the latest summary on national numbers and trends, and the actions we all need to be taking to reduce infection rates, while vaccination programs expand for the protection of all Canadians. Due to reduced reporting over the weekend, national seven-day averages have not been updated in today’s statement. These data are still being collected and analysed. I will provide the latest numbers during my remarks tomorrow.

Since the start of the pandemic, there have been 909,157 cases of COVID-19, including 22,463 deaths reported in Canada ; these cumulative numbers tell us about the overall burden of COVID-19 illness to date. They also tell us, together with results of serological studies, that the vast majority of Canadians remain susceptible to COVID-19 . As vaccination programs continue to expand across Canada , there is growing optimism that widespread and lasting immunity can be achieved through COVID-19 vaccination. We now have multiple safe and effective COVID-19 vaccines with unique advantages that are authorised for use in Canada . Recent expert analysis of the efficacy and effectiveness of COVID-19 vaccines in Canada supports that priority vaccination programs are providing strong benefits for those at highest risk of severe outcomes or exposure. These encouraging findings have created opportunities for the safe and effective adjustment of vaccination programs to protect the entire adult population within a short timeframe, while contributing to health equity .

Currently, there are 31,674 active cases across the country. Although COVID-19 activity has been levelling off nationally over several weeks, average daily case counts remain high and we are now observing a recent increase. The latest national-level data show a 7-day average of 3,052 new cases daily ( Mar 5-11 ). While COVID-19 continues to impact people of all ages in Canada , infection rates are now highest among those aged 20-39 years of age. Circulation of COVID-19 in younger, more mobile and socially-connected adults can increase the risk of spread into high-risk populations and settings. The emergence and spread of certain SARS-CoV-2 virus variants heightens this concern. For the week of February 28 – March 6 , there were on average of 104,332 tests completed daily across Canada , of which 2.9 % were positive for COVID-19. As of March 14 , a total of 3,302 variants of concern have been reported across Canada , including 3,031 B .1.1.7 variants, 220 B .1.351 variants and 51 P.1 variants. With the continued increase of cases and outbreaks associated with more contagious variants, we must all remain vigilant with public health measures and individual precautions to prevent a rapid shift in trajectory of the epidemic.

Nationally, severe outcomes continue to decline. Provincial and territorial data indicate that an average of 2,056 people with COVID-19 were being treated in Canadian hospitals each day during the most recent 7-day period ( Mar 5-11 ), including 542 of whom were being treated in intensive care units. During the same period, there were an average of 31 COVID-19-related deaths reported daily.

While vaccine programs begin to accelerate, it will be important to maintain a high degree of caution. Any easing of public health measures must be done slowly with enhanced testing, screening, and genomic analysis to detect variants of concern. In particular, there must be sufficient contact tracing capacity and supports for effective isolation, given increased transmissibility of variants of concern.

Canadians are urged to remain vigilant, continue following local public health advice, and consistently maintain individual practices that keep us and our families safer: stay home/self-isolate if you have any symptoms , think about the risks and reduce non-essential activities and outings to a minimum, avoid all non-essential travel , and maintain individual protective practices of physical distancing , hand, cough and surface hygiene and wearing a well-fitted and properly worn face mask as appropriate (including in shared spaces, indoors or outdoors, with people from outside of your immediate household).

Aiming to have the fewest interactions with the fewest number of people , for the shortest time , at the greatest distance possible, while wearing the best-fitting mask is a simple rule that we can all apply to help limit the spread of COVID-19, as vaccine programs expand to protect all Canadians.

Canadians can also go the extra mile by sharing credible information on COVID-19 risks and prevention practices and measures to reduce COVID-19 in communities and by downloading the COVID Alert app to break the cycle of infection and help limit the spread of COVID-19. Read my backgrounder to access more COVID-19 Information and Resources on ways to reduce the risks and protect yourself and others, including information on COVID-19 vaccination .

SOURCE Public Health Agency of Canada

Cision View original content: http://www.newswire.ca/en/releases/archive/March2021/15/c2548.html

Let’s block ads! (Why?)



Source link

Continue Reading

Health

Canada will not restrict AstraZeneca COVID-19 vaccine, says benefits outweigh risk

Published

 on

OTTAWA (Reuters) – Canada‘s health ministry said on Wednesday it would not restrict use of AstraZeneca Plc’s COVID-19 vaccine after a review showed the benefits outweighed the very rare risk of blood clots.

A separate advisory council had earlier recommended Canada stop offering the vaccine to people under 55. The panel is now reviewing that advice, the health ministry said in a statement.

Denmark on Wednesday became the first country to stop using the vaccine altogether over a potential link to the rare blood clots. Other nations have imposed limits on its use.

But Health Canada, the federal health ministry, said in a statement that a review of data from Europe, Britain and AstraZeneca had not identified specific risk factors.

“Therefore, Health Canada is not restricting the use of the vaccine in any specific populations at this time … The potential risk of these events is very rare, and the benefits of the vaccine in protecting against COVID-19 outweigh its potential risks,” it said.

Canada on Tuesday said it had recorded its first case of blood clotting with low platelets after someone received the AstraZeneca shot. The patient in question, a woman from Quebec, is recovering. (Graphic on vaccines: https://tmsnrt.rs/3tUM8ta)

COVID-19 cases are surging in Canada with the country reporting a near-record number of new cases recently. (Graphic on cases: https://tmsnrt.rs/34pvUyi)

 

(Reporting by David Ljunggren in Ottawa and Allison Martell in Toronto; Editing by Lisa Shumaker)

Continue Reading

Health

Factbox-Some countries limit AstraZeneca vaccine use, US pauses J&J shot

Published

 on

(Reuters) -Some countries are restricting use of the AstraZeneca COVID-19 vaccine to certain age groups or suspending use after European and British regulators confirmed possible links to rare blood clots.

Denmark became the first country to stop using the vaccine altogether, as it said results of investigations showed “real and serious side-effects”.

Johnson & Johnson’s single-shot vaccine has also been hit by concerns over blood clots, with European regulators reviewing such cases and U.S. federal health agencies recommending pausing its use for a few days. J&J noted no clear causal relationship had been established between the clots and its vaccine.

The developments pose a risk to vaccination plans in Europe.

Regulators have said the benefits of the AstraZeneca shot outweigh risks.

Anglo-Swedish drugmaker AstraZeneca said it was working with regulators to list the possible brain blood clots as “an extremely rare potential side effect” on the vaccines labels.

As of April 4, the European Medicines Agency had received reports of 169 cases of a rare brain blood clot known as cerebral venous sinus thrombosis (CVST), after 34 million doses had been administered in the European Economic Area. Most cases were in women under 60 years of age.

ASTRAZENECA VACCINE BEING USED, WITH OR WITHOUT RESTRICTIONS

AUSTRALIA

Said on April 8 it recommends people under 50 should get Pfizer’s COVID-19 vaccine in preference to AstraZeneca’s shot.

AUSTRIA

Has resumed use.

BRAZIL

Authorities said they would not limit use of the AstraZeneca vaccine, saying benefits outweigh risks.

BRITAIN

The Joint Committee on Vaccination and Immunisation has said an alternative to the vaccine should be given for people under 30 where possible, but people should continue to have a second shot if they have received a first dose.

BULGARIA

Resumed inoculations from March 19.

CYPRUS

Resumed inoculations on March 19.

CANADA

Authorities said in early April they would pause offering the vaccine to people under 55 and require a new analysis of the shot’s benefits and risks based on age and gender. On April 13, the country said it had recorded its first case of blood clotting with low platelets.

ESTONIA

Suspended use of the vaccine for people under 60 on April 7.

FRANCE

Approved resumption of the vaccine on March 19 but said it should be given only to people aged 55 and over. On April 9, recommended that recipients of a first dose of the AstraZeneca shot who are under 55 should receive a second dose with a messenger RNA vaccine.

FINLAND

Resumed using the AstraZeneca vaccine from March 29, but only for people aged 65 and over.

GEORGIA

Has limited use of the vaccine following the death of a nurse from anaphylactic shock, and vaccinations will continue only in full-fledged medical centres, Russian news agency TASS reported on March 19.

GERMANY

Sticking to its guidance from March 31 to limit use of the vaccine to those aged over 60. On April 1, Germany’s vaccine commission recommended people under 60 who have had a first shot of the vaccine should receive a different product for their second dose.

HUNGARY

Continuing the vaccine’s rollout.

ICELAND

Resumed use on March 25 after suspending it on March 11.

INDONESIA

Resumed using the vaccine on March 22 but warned against its use in people with a low blood platelet count.

IRELAND

On April 12, the country said it was restricting use of the vaccine to those over 60.

ITALY

Has recommended the vaccine be used only for people over 60, the country’s top health adviser said.

LATVIA

Announced it was restarting administering the shots from March 19.

LITHUANIA

Restarted use on March 19.

MEXICO

Drug regulator Cofepris said on April 7 it did not “at this time” plan to limit the vaccine’s use but was investigating the information raised by Britain.

NETHERLANDS

Limited use of the vaccine to people over 60, the Dutch government said on April 8.

NORTH MACEDONIA

Health minister said on March 31 the vaccine would be limited to people aged over 60 as a precautionary measure.

PHILIPPINES

Suspended use of the vaccine for people under 60 on April 8.

ROMANIA

Has resumed use of the vaccine after temporarily stopping vaccinating people with one batch of the vaccine on March 11.

SOUTH KOREA

Resumed use of the shot for people aged 30 or older on April 12. On April 7, it had suspended providing the AstraZeneca shot to people under 60.

SPAIN

From April 8, it was giving the vaccine only to people over 60.

SWEDEN

Resumed use of the vaccine on March 25 for people aged 65 and older.

THAILAND

Began use on March 15 after delaying rollout the week before.

COUNTRIES WHERE ASTRAZENECA VACCINE USE SUSPENDED

CAMEROON

Suspended administration of the vaccine it was scheduled to receive on March 20 as part of the global vaccines sharing scheme COVAX, the health ministry said.

DENMARK

In a world first, Denmark decided to stop using the AstraZeneca vaccine altogether after initially suspending use of the shot.

NORWAY

Authorities said on March 26 Norway would delay a decision on use of the vaccine, with a decision expected by April 15.

J&J VACCINE DELAYS AND RESTRICTIONS

UNITED STATES

On April 13, U.S. federal health agencies recommended pausing use of J&J’s COVID-19 vaccine for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot.

EUROPEAN UNION

The company said it would delay the rollout of the vaccine to Europe, after regulators said they were reviewing rare blood clots.

Widespread use in the EU had not yet started after the company began delivering the doses in the week beginning April 12. The European drug regulator recommended storing doses already received until its safety committee issues an expedited recommendation

SOUTH AFRICA

Suspended use of J&J’s vaccine on April 13.

(Reporting by Pushkala Aripaka, Yadarisa Shabong, Manas Mishra, Vishwadha Chander, Amruta Khandekar and Mrinalika Roy in Bengaluru; editing by Josephine Mason, Alison Williams, Timothy Heritage, Larry King, Barbara Lewis)

Continue Reading

Health

Ontario hospitals may have to withhold care as COVID-19 fills ICUs

Published

 on

By Allison Martell and Anna Mehler Paperny

TORONTO (Reuters) – Doctors in the Canadian province of Ontario may soon have to decide who can and cannot receive treatment in intensive care as the number of coronavirus infections sets records and patients are packed into hospitals still stretched from a December wave.

Canada‘s most populous province is canceling elective surgeries, admitting adults to a major children’s hospital and preparing field hospitals after the number of COVID-19 patients in ICUs jumped 31% to 612 in the week leading up to Sunday, according to data from the Ontario Hospital Association.

The sharp increase in Ontario hospital admissions is also straining supplies of tocilizumab, a drug often given to people seriously ill with COVID-19.

Hospital care is publicly funded in Canada, generally free at the point of care for residents. But new hospital beds have not kept pace with population growth, and shortages of staff and space often emerge during bad flu seasons.

Ontario’s hospitals fared relatively well during the first wave of the pandemic last year, in part because the province quickly canceled elective surgeries.

The College of Physicians and Surgeons of Ontario told doctors last Thursday that the province was considering “enacting the critical care triage protocol,” something that was not done during earlier waves of the virus. Triage protocols help doctors decide who to treat in a crisis.

“Everybody’s under extreme stress,” said Eddy Fan, an ICU doctor at Toronto’s University Health Network. He said no doctor wants to contemplate a triage protocol but there are only so many staff.

“There’s going to be a breaking point, a point at which we can’t fill those gaps any longer.”

In a statement, the health ministry said Ontario has not activated the protocol. A September draft suggested doctors could withhold life-sustaining care from patients with a less than 20% chance of surviving 12 months. A final version has not been made public.

Ontario’s Science Advisory Table had been forecasting the surge for months, said member and critical care physician Laveena Munshi. During a recent shift she wanted to call the son of a patient only to discover he was in an ICU across the street.

“The horror stories that we’re seeing in the hospital are like ones out of apocalyptic movies,” she said. “They’re not supposed to be the reality we’re seeing one year into a pandemic.”

Continue Reading

Trending